Testing effectiveness (Phase 2)Study completedNCT02335411
What this trial is testing
Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 318